Aligos Therapeutics, Inc.
ALGS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$131,211 | -$87,679 | -$96,046 | -$128,332 |
| Dep. & Amort. | $2,622 | $3,069 | $3,675 | $3,778 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $8,452 | $12,652 | $0 | $13,457 |
| Change in WC | -$4,955 | -$9,525 | -$1,552 | -$4,651 |
| Other Non-Cash | $44,349 | $2,486 | $14,534 | $86 |
| Operating Cash Flow | -$80,743 | -$78,997 | -$79,389 | -$115,662 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$130 | -$19 | -$943 | -$892 |
| Net Acquisitions | $0 | $0 | $0 | -$3,914 |
| Inv. Purchases | -$108,149 | -$11 | -$104,265 | -$19,086 |
| Inv. Sales/Matur. | $90,000 | $45,011 | $78,915 | $23,000 |
| Other Inv. Act. | $0 | $0 | $0 | $3,914 |
| Investing Cash Flow | -$18,279 | $44,981 | -$26,293 | $3,022 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$83 | -$96 | -$61 | -$79 |
| Stock Issued | $438 | $17,443 | $225 | $78,584 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $0 | $70,981 | $0 | $172 |
| Financing Cash Flow | $355 | $88,328 | $164 | $78,677 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$98,667 | $54,312 | -$105,518 | -$33,963 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $135,774 | $81,462 | $186,980 | $220,943 |
| End Cash | $37,107 | $135,774 | $81,462 | $186,980 |
| Free Cash Flow | -$80,873 | -$79,016 | -$80,332 | -$116,554 |